Last reviewed · How we verify
NCT05367518
Colonisation Efficacy of Oral Probiotic Fast Melt Powder
NA trial testing Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g) in Microbial Colonization in 20 participants. Status unknown.
25 May 2022
Quick facts
| Lead sponsor | BLIS Technologies Limited |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 15 May 2022 |
| Primary completion | 25 May 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)
- Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)
Conditions studied
- Microbial Colonization — all drugs for Microbial Colonization →
Sponsor
BLIS Technologies Limited
Who can join
Adults 18 to 80, any sex, with Microbial Colonization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the colonisation efficacy (i.e. ability of the probiotic bacteria to remain in your mouth) of a fast melt powder that quickly dissolves in the mouth. The fast melt powder will contain a Streptococcus salivarius probiotic and the study is to be done in healthy adults.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05367518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Microbial Colonization
Currently open trials in the same condition.
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT06805994 — Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment · Phase 1 · recruiting
- NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
- NCT06920641 — Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults · NA · recruiting
- NCT06541808 — Balance, Autonomic Response, and Sensory Modulation to Dosage of Mechanical Vagal Stimulation in Healthy Adults · NA · recruiting
Other BLIS Technologies Limited trials
Trials by the same sponsor.
- NCT06166979 — Colonisation of Scalp by Topical Probiotic Micrococcus Luteus Q24 · NA · completed
- NCT06137209 — Colonization of Skin by M. Luteus Q24 Probiotic · NA · unknown
- NCT06015958 — Probiotic Toothpaste to Assess Microbial Colonization · NA · unknown
- NCT05750381 — Assessment of Colonisation and Skin Quality Parameter Improvement by Probiotic Micrococcus Luteus Q24 Balm in Healthy Ad · NA · unknown
- NCT05375383 — Microbial Colonization of Oral Probiotics · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05367518 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BLIS Technologies Limited
- Last refreshed: 10 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing